The complexity of cGAS–STING signaling, coupled with tumor-intrinsic resistance mechanisms, an immunosuppressive TME, and the risk of exacerbated immune-related toxicities, presents formidable barriers to clinical success. This evidence concerns the gene STING1 and neoplasm.